Brokerages Set TuHURA Biosciences, Inc. (NASDAQ:HURA) PT at $9.00

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $9.00.

HURA has been the topic of several research analyst reports. Citizens Jmp reaffirmed a “market outperform” rating and set a $9.00 target price on shares of TuHURA Biosciences in a research note on Tuesday, August 18th. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Friday, July 17th. Wall Street Zen downgraded shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, May 31st. Finally, Citigroup assumed coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued an “outperform” rating on the stock.

TuHURA Biosciences Stock Performance

Shares of TuHURA Biosciences stock opened at $2.15 on Tuesday. The stock has a market cap of $137.02 million, a PE ratio of -3.98 and a beta of -0.01. The business has a fifty day simple moving average of $2.28 and a 200-day simple moving average of $2.08. The company has a quick ratio of 0.18, a current ratio of 0.18 and a debt-to-equity ratio of 0.20. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $3.43.

TuHURA Biosciences (NASDAQ:HURA) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. On average, sell-side analysts anticipate that TuHURA Biosciences will post -0.57 EPS for the current fiscal year.

Hedge Funds Weigh In On TuHURA Biosciences

A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in TuHURA Biosciences in the 2nd quarter worth about $1,615,000. Geode Capital Management LLC lifted its holdings in shares of TuHURA Biosciences by 111.4% during the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock valued at $1,300,000 after buying an additional 307,260 shares during the last quarter. Cetera Investment Advisers acquired a new stake in shares of TuHURA Biosciences during the 1st quarter valued at about $251,000. Bank of New York Mellon Corp bought a new stake in shares of TuHURA Biosciences in the 2nd quarter valued at approximately $285,000. Finally, WealthShield Partners LLC bought a new stake in shares of TuHURA Biosciences in the 2nd quarter valued at approximately $214,000. 0.62% of the stock is owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.